Company Valuation: BriaCell Therapeutics Corp.

Data adjusted to current consolidation scope
Fiscal Period: July 2020 2021 2022 2023 2024 2025
Market Cap 1 5.148 78.61 101.5 106.4 13.63 12.81
Change - 1,427.04% 29.07% 4.9% -87.19% -6.05%
Enterprise Value (EV) 1 5.429 21.37 60.42 85.18 12.77 -5.058
Change - 293.6% 182.77% 40.98% -85.01% -139.6%
P/E - -54.3x -3.77x -5.12x -2.56x -0.12x
PBR - 1.37x 9.82x -28.2x -5.72x 0.77x
PEG - - -0x 0.2x 0x -0x
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -1.13x -3.07x -3.96x -3.66x -0.38x 0.19x
EV / EBIT -1.12x -3.06x -3.95x -3.66x -0.38x 0.19x
EV / FCF 21x -3.65x -8.81x -5.37x -1.18x 0.27x
FCF Yield 4.77% -27.4% -11.3% -18.6% -84.8% 374%
Dividend per Share 3 - - - - - -
Rate of return - - - - - -
EPS 3 - -14.22 -259.8 -195 -43.68 -62.19
Distribution rate - - - - - -
Net sales - - - - - -
EBITDA 1 -4.821 -6.958 -15.27 -23.26 -33.25 -27.1
EBIT 1 -4.84 -6.973 -15.29 -23.27 -33.33 -27.2
Net income 1 -4.944 -0.4283 -26.84 -20.3 -4.791 -26.31
Net Debt 1 0.2808 -57.24 -41.04 -21.25 -0.8621 -17.87
Reference price 3 1,069.572 772.222 980.759 998.928 111.849 7.298
Nbr of stocks (in thousands) 4.81 102 103 107 122 1,755
Announcement Date 30/11/20 28/10/21 27/10/22 25/10/23 29/10/24 15/10/25
1USD in Million2CAD in Million3USD
Estimates

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 3.51Cr
21.45x7.54x15.37x1.38% 7.21TCr
37.53x9.72x29.82x0.04% 6.59TCr
-18.08x7.59x-9.85x-.--% 2.93TCr
-79.5x14.86x-71.64x-.--% 2.75TCr
33.76x6.66x17.64x-.--% 2.67TCr
27.2x5.1x17.12x-.--% 2.01TCr
52.91x19.58x39.65x0.29% 1.82TCr
2460.33x41.28x-5047.29x-.--% 1.64TCr
16.73x4.96x11.58x-.--% 1.34TCr
Average 283.59x 13.03x -555.29x 0.19% 2.9TCr
Weighted average by Cap. 153.01x 11.04x -277.31x 0.37%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. BCT Stock
  4. Valuation BriaCell Therapeutics Corp.